14 March 2022 in Cardiovascular Therapeutics
Myocardial remodeling is one of the main lesions in the late stage of chronic heart failure and seriously affects the prognosis of patients. Continuous activation of the renin-angiotensin-aldosterone system (RAAS) contributes to the development of myocardial remodeling greatly, and angiotensin II (Ang II), its main constituent, can directly lead to cardiac remodeling through an inflammatory response and oxidative stress. Since Ang II-induced myocardial remodeling is closely related to inflammation, we tried to explore whether the anti-inflammatory drug oridonin (Ori) can reverse this process and its possible mechanism. Our study investigated that hypertrophy and fibrosis can be induced after being treated with Ang II in cardiomyocytes (H9c2 cells and primary rat cardiomyocytes) and C57BL/6J mice. The anti-inflammatory drug oridonin could effectively attenuate the degree of cardiac remodeling both in vivo and vitro by inhibiting GSDMD, a key protein of intracellular inflammation which can further activate kinds of inflammation factors such as IL-1β and IL-18. We illustrated that oridonin reversed cardiac remodeling by inhibiting the process of inflammatory signaling through GSDMD. After inhibiting the expression of GSDMD in cardiomyocytes by siRNA, it was found that Ang II-induced hypertrophy was attenuated. These results suggest that oridonin is proved to be a potential protective drug against GSDMD-mediated inflammation and myocardial remodeling.
26 February 2026 in Clinical and Translational Medicine
Background: Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for the pathogenesis of numerous cardiovascular diseases; nevertheless, its function in the process of cardiac ageing remains uncertain. Methods: This study utilised P2X7R knockout (P2X7R − / − ) mice. An ageing model was established by either maintaining mice until they reached 20 months of age or performing chronic subcutaneous injection of D‐galactose (D‐gal). Recombinant adeno‐associated virus serotype 9 (AAV9) was employed to achieve cardiac‐specific overexpression of P2X7R and nuclear receptor subfamily 4 group A member 1 (NR4A1). Cardiac function and histopathological changes in cardiac tissues were evaluated. Transcriptome sequencing was further applied to elucidate the potential mechanisms of P2X7R in cardiac senescence. Result: Our result show that serum levels of P2X7R increase with advancing age in humans and that P2X7R expression is upregulated during cardiac senescence in mice. P2X7R deficiency alleviates ageing‐related cardiac dysfunction, senescence phenotypes and impaired mitophagy. Cardiomyocyte‐specific overexpression of P2X7R with AAV9 exacerbates the myocardial dysfunction, senescence phenotype and mitophagy disruption induced by D‐gal. Mechanistically, P2X7R promotes human antigen R (HuR) nucleocytoplasmic shuttling in ageing hearts, thereby increasing the mRNA stability of tripartite motif containing 26 (TRIM26) and the expression of the E3 ubiquitin ligase TRIM26. TRIM26 subsequently mediates NR4A1 ubiquitination, leading to its proteasomal degradation, which subsequently suppresses mitophagy in cardiomyocytes and ultimately accelerates cardiac ageing. Conclusions: Our findings provide valuable insights into the role of P2X7R in cardiac ageing and identify the HuR/TRIM26/NR4A1 axis as a key signalling pathway through which P2X7R regulates cardiac ageing.